
SUPPORTING INFORMATION

Discovery of (*S*)-3'-hydroxyblebbistatin and (*S*)-3'-aminoblebbistatin: polar myosin II inhibitors with superior research tool properties

Sigrid Verhasselt,^[a] Bart I. Roman,^{[a]*} Olivier De Wever,^[b] Kristof Van Hecke,^[c] Rik Van Deun,^[c] Marc E. Bracke,^[b] and Christian V. Stevens^{[a]*}

[a] SynBioC Research Group, Department of Sustainable Organic Chemistry and Technology, Ghent University, Coupure Links 653, 9000 Ghent (Belgium)

*E-mail: bartl.roman@ugent.be, chris.stevens@ugent.be

[b] Laboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University, De Pintelaan 185, 9000 Ghent (Belgium)

[c] Department of Inorganic and Physical Chemistry, Ghent University, Krijgslaan 281 S3, 9000 Ghent (Belgium)

Table of contents

1. Synthetic protocols and compound characterization

1.1. Reagents and materials

1.2. Synthesis of aryl iodide **4b**

1.3. Synthesis of aryl iodide **4c**

1.4. Synthesis of tris(3,5-dimethyl-1*H*-pyrazolyl-1-yl)methane (**S5**)

1.5. General procedure for the *N*-arylation of 2-pyrrolidinone with aryl iodides

1.5.1. Synthesis of pyrrolidinone **6a**

1.5.2. Synthesis of pyrrolidinone **6b**

1.5.3. Synthesis of pyrrolidinone **6d**

1.6. Synthesis of pyrrolidinone **6c**

1.7. Synthesis of pyrrolidinethione **10**

1.8. Synthesis of methyl 2-amino-5-methylbenzoate (**7**)

1.9. General procedure for the synthesis of amidines from pyrrolidinones

1.9.1. Synthesis of amidine **8a**

1.9.2. Synthesis of amidine **8b**

1.9.3. Synthesis of amidine **8d**

1.10. General procedure for the synthesis of quinolones from amidines

1.10.1. Synthesis of quinolone **9a**

1.10.2. Synthesis of quinolone **9b**

1.10.3. Synthesis of quinolone **9d**

1.11. Synthesis of (*S*)-3'-diallylaminoblebbistatin ((*S*)-**12**) and (*S*)-3'-diallylaminoblebbistatin ((*S*)-**12**)

1.12. Synthesis of diazomethane (CH₂N₂)

2. X-ray crystallographic data

2.1. X-ray crystallographic data of (*S*)-**2**

Figure S1. Molecular structure of compounds (*S*)-**2**, showing thermal displacement ellipsoids at the 50% probability level and atom labeling scheme of the non-hydrogen atoms.

Figure S2. Packing in the crystal structure of compound (*S*)-**2**, along the *a*-axis.

2.2. X-ray crystallographic data of (*R*)-2

Figure S3. Molecular structure of compounds (*R*)-2, showing thermal displacement ellipsoids at the 50% probability level and atom labeling scheme of the non-hydrogen atoms.

Figure S4. Packing in the crystal structure of compound (*R*)-2, along the a-axis.

3. ¹H NMR spectra, ¹³C NMR spectra and LC-MS chromatograms

Figure S5. ¹H NMR spectrum of **4b**.

Figure S6. ¹H NMR spectrum of **4c**.

Figure S7. ¹³C NMR spectrum of **4c**.

Figure S8. ¹H NMR spectrum of **S5**.

Figure S9. ¹H NMR spectrum of **6a**.

Figure S10. ¹H NMR spectrum of **6b**.

Figure S11. ¹³C NMR spectrum of **6b**.

Figure S12. ¹H NMR spectrum of **6d**.

Figure S13. ¹³C NMR spectrum of **6d**.

Figure S14. ¹H NMR spectrum of **6c**.

Figure S15. ¹³C NMR spectrum of **6c**.

Figure S16. ¹H NMR spectrum of **10**.

Figure S17. ¹³C NMR spectrum of **10**.

Figure S18. ¹H NMR spectrum of **7**.

Figure S19. ¹H NMR spectrum of **8a**.

Figure S20. ¹H NMR spectrum of **8b**.

Figure S21. ¹³C NMR spectrum of **8b**.

Figure S22. ¹H NMR spectrum of **8d**.

Figure S23. ¹³C NMR spectrum of **8d**.

Figure S24. ¹H NMR spectrum of **9a**.

Figure S25. ¹H NMR spectrum of **9b**.

Figure S26. ¹³C NMR spectrum of **9b**.

Figure S27. ¹H NMR spectrum of **9d**.

Figure S28. ^{13}C NMR spectrum of **9d**.

Figure S29. ^1H NMR spectrum of (*S*)-**1**.

Figure S30. ^1H NMR spectrum of (*S*)-**11**.

Figure S31. ^{13}C NMR spectrum of (*S*)-**11**.

Figure S32. ^1H NMR spectrum of (*S*)-**13**.

Figure S33. ^{13}C NMR spectrum of (*S*)-**13**.

Figure S34. ^1H NMR spectrum of (*S*)-**12**.

Figure S35. ^{13}C NMR spectrum of (*S*)-**12**.

Figure S36. ^1H NMR spectrum of (*S*)-**2**.

Figure S37. ^{13}C NMR spectrum of (*S*)-**2**.

Figure S38. ^1H NMR spectrum of (*S*)-**3**.

Figure S39. ^{13}C NMR spectrum of (*S*)-**3**.

Figure S40. ^1H NMR spectrum of (*S*)-**16**.

Figure S41. ^{13}C NMR spectrum of (*S*)-**16**.

Figure S42. ^1H NMR spectrum of (*S*)-**17**.

Figure S43. ^{13}C NMR spectrum of (*S*)-**17**.

Figure S44. Proof of formation of corresponding methyl ester of (*S*)-**17** via ^1H NMR (overlay of (*S*)-**17**).

Figure S45. Proof of formation of corresponding methyl ester of (*S*)-**17** via LC.

Figure S46. Proof of formation of corresponding methyl ester of (*S*)-**17** via MS (MS-spectrum of compound with $t_{\text{R}} = 0.324$ min in Figure S45).

Figure S47. Proof of formation of corresponding methyl ester of (*S*)-**17** via MS (MS-spectrum of compound with $t_{\text{R}} = 2.606$ min in Figure S45).

4. Chiral HPLC chromatograms

Figure S48. Chiral HPLC chromatogram of (*S*)-**1** spiked with (*R*)-**1**.

Figure S49. Chiral HPLC chromatogram of (*S*)-**1**.

Figure S50. Chiral HPLC chromatogram of (*R*)-**1**.

Figure S51. Chiral HPLC chromatogram of (*S*)-**11** spiked with (*R*)-**11**.

Figure S52. Chiral HPLC chromatogram of (*S*)-**11**.

Figure S53. Chiral HPLC chromatogram of (*R*)-**11**.

Figure S54. Chiral HPLC chromatogram of (*S*)-**13** spiked with (*R*)-**13**.

Figure S55. Chiral HPLC chromatogram of (*S*)-**13**.

Figure S56. Chiral HPLC chromatogram of (*R*)-**13**.

Figure S57. Chiral HPLC chromatogram of (*S*)-**12** spiked with (*R*)-**12**.

Figure S58. Chiral HPLC chromatogram of (*S*)-**12**.

Figure S59. Chiral HPLC chromatogram of (*R*)-**12**.

Figure S60. Chiral HPLC chromatogram of (*S*)-**2** spiked with (*R*)-**2**.

Figure S61. Chiral HPLC chromatogram of (*S*)-**2**.

Figure S62. Chiral HPLC chromatogram of (*R*)-**2**.

Figure S63. Chiral HPLC chromatogram of (*S*)-**3** spiked with (*R*)-**3**.

Figure S64. Chiral HPLC chromatogram of (*S*)-**3**.

Figure S65. Chiral HPLC chromatogram of (*R*)-**3**.

Figure S66. Chiral HPLC chromatogram of (*S*)-**16** spiked with (*R*)-**16**.

Figure S67. Chiral HPLC chromatogram of (*S*)-**16**.

Figure S68. Chiral HPLC chromatogram of (*R*)-**16**.

Figure S69. Chiral HPLC chromatogram of corresponding methyl ester of (*S*)-**17** spiked with corresponding methyl ester of (*R*)-**17**.

Figure S70. Chiral HPLC chromatogram of corresponding methyl ester of (*S*)-**17**.

Figure S71. Chiral HPLC chromatogram of corresponding methyl ester of (*R*)-**17**.

5. Actin-activated ATPase assay

Figure S72. Observed (*S*)-**13** precipitation in assay buffer when applied at concentrations higher than 40 μ M.

6. Microscopic imaging of fluorescence

Figure S73. Fluorescence imaging of GFP-negative MCF-7/6 breast carcinoma cells treated with 0.1% DMSO as a solvent control.

Figure S74. Fluorescence imaging of GFP-negative MCF-7/6 breast carcinoma cells treated with 5 μ M of (*S*)-3'-aminoblebbistatin (*S*)-**3**.

Figure S75. Fluorescence imaging of GFP-negative MCF-7/6 breast carcinoma cells treated with (*S*)-3'-hydroxyblebbistatin (*S*)-**2**.

7. References

1. Synthetic protocols and compound characterization

1.1. Reagents and materials

Dichloromethane was dried by heating under reflux over CaH_2 and distilled under an atmosphere of nitrogen. Tetrahydrofuran was dried by heating under reflux with sodium/benzophenone under a nitrogen atmosphere and collected by distillation. Dry 1,4-dioxane and dry methanol were purchased from Sigma-Aldrich and Acros Organics, respectively. Reagents were purchased at the highest commercial quality and were used as received without further purification.


Yields refer to chromatographically and spectroscopically (^1H NMR) homogeneous material, unless otherwise stated.

Reactions were monitored on an Agilent 1200 series HPLC system fitted with an Ascentis® Express C18-column (2.7 μm particle size, 4.6 mm internal diameter), using acetonitrile/water (5 mM NH_4OAc) as eluent. Low-resolution mass spectra were recorded on an Agilent 1100 series VL mass spectrometer (ESI, 70 eV). High-resolution mass spectra (HRMS) were recorded using an Agilent Technologies 6210 series time-of-flight (TOF) mass spectrometer equipped with an ESI/APCI-multimode source. Thin layer chromatography (TLC) was carried out on 0.25 mm Merck silica plates (60 F_{254}) and spots were visualized by UV light (254 nm). Flash column chromatography was performed on an automated Reveleris® X2 flash chromatography system, using Reveleris® C18 or Reveleris® silica cartridges. Melting points were determined using a Wagner & Munz WME Heizbank Kofler bench.

NMR spectra were recorded on a Bruker Avance III instrument. ^1H NMR (400 MHz) chemical shifts are recorded in CDCl_3 or DMSO-d_6 , reported in ppm and measured relative to tetramethylsilane or the residual undeuterated solvent as the internal reference, respectively. ^{13}C NMR (100.6 MHz) chemical shifts are reported in ppm and were measured relative to the residual undeuterated solvent as the internal reference. The following abbreviations were used to explain NMR peak multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, br = broad.

The enantiomeric excess (ee) of chiral compounds was determined *via* chiral HPLC analysis using a Daicel Chiralpak IA column (5 μm particle size, 150 mm length, 2.1 mm internal diameter). Detection wavelengths were set at 268, 234 and 296 nm. Analyses under reversed phase and normal phase conditions were performed at 25 °C and 35 °C, respectively. Optical rotations were obtained on a Jasco P-2000 polarimeter and are reported in $\text{deg mL g}^{-1} \text{ dm}^{-1}$; concentrations are reported in grams per 100 mL.


1.2. Synthesis of aryl iodide **4b**



Allylation of 3-iodophenol (**S1**) to afford aryl iodide **4b** was based on a publication of Brown Ripin and Vetelino.¹


In a bulb of 500 mL containing 225 mL of 2-methyltetrahydrofuran, 39.0 g of 3-iodophenol (**S1**) (177 mmol, 1 equiv), 340 mL of 25% aqueous NaOH, 0.857 g of tetra-*n*-butylammonium bromide (2.66 mmol, 0.015 equiv) and 16.2 mL of allyl bromide (186 mmol, 1.05 equiv) were brought together. The resulting mixture was stirred under reflux for 2 hours, cooled down to room temperature and diluted with 350 mL of diethyl ether and 175 mL of water. The two layers were separated and the aqueous layer was extracted with 350 mL of diethyl ether. The combined organic layers were concentrated under reduced pressure to a volume of 350 mL, washed with 175 mL of brine and dried over magnesium sulfate. Evaporation *in vacuo* afforded aryl iodide **4b** (46.1 g, quant.) as a yellow-orange oil.

1-(Allyloxy)-3-iodobenzene (**4b**)^{2,3}



Yield = quant. Yellow-orange oil. ¹H NMR (400 MHz, CDCl₃): δ = 4.50 (dt, J = 5.2, 1.4 Hz, 2H), 5.29 (dq, J = 10.5, 1.4 Hz, 1H), 5.40 (dq, J = 17.3, 1.4 Hz, 1H), 6.02 (ddt, J = 17.3, 10.5 Hz, 1H), 6.85–6.90 (m, 1H), 6.99 (t, J = 8.0 Hz, 1H), 7.26–7.28 (m, 1H), 7.26–7.30 (m, 1H). **MW** = 260.07. ¹H NMR spectrum is provided in Figure S5.


1.3. Synthesis of aryl iodide 4c



The allylation of 3-iodoaniline (**S2**) to produce aryl iodide **4c** was based on a publication of Vandekerckhove et al.⁴


A bulb of 500 mL, equipped with an oven-dried reflux condenser and kept under a nitrogen atmosphere, was loaded with 100 mL of dry tetrahydrofuran and 11.5 mL of 3-iodoaniline (**S2**) (95.6 mmol, 1 equiv). Then, the solution was cooled to 0 °C and 120 mL of lithiumbis(trimethylsilyl)amide (1 M solution in tetrahydrofuran, 120 mmol, 1.25 equiv) and 33.1 mL of allyl bromide (382 mmol, 4 equiv) were added. The reaction was stirred for 2 hours at reflux temperature. Next, the solution was cooled to 0 °C, a second portion of lithiumbis(trimethylsilyl)amide (1 M solution in tetrahydrofuran, 120 mL, 120 mmol, 1.25 equiv) was added and the reaction mixture was refluxed for 1 hour. The solution was again cooled to 0 °C, a third portion of lithiumbis(trimethylsilyl)amide (1 M solution in tetrahydrofuran, 47.8 mL, 47.8 mmol, 0.5 equiv) was added and the solution was stirred for another hour at reflux temperature. Subsequently, the mixture was cooled down to room temperature, quenched with 800 mL of saturated aqueous NH_4Cl and evaporated under reduced pressure. The residual aqueous layer was extracted with an equal volume of ethyl acetate (3 \times). The combined organic layers were concentrated *in vacuo* to a volume of 600 mL, washed with an equal volume of saturated aqueous NaHCO_3 and brine. Drying with magnesium sulfate and evaporation *in vacuo* resulted in a red oil. The side product *N,N*-bis(trimethylsilyl)allylamine (**S3**) was distilled off (20 mbar, 56–63 °C). The residue (28.8 g) was dissolved in 17 mL of hexane and half of the total volume was manually injected on a Reveleris® 120 g silica cartridge (12% sample loading) for purification *via* automated flash chromatography (flow rate: 80 mL min^{-1} ; eluent: 7 CV of 100% hexane, followed by 4 CV of 100% ethyl acetate; detection wavelength: 254 nm). The same conditions were applied to purify the other half of the crude mixture. Evaporation of the combined fractions resulted in aryl iodide **4c** (21.4 g, 75%) as a yellow oil.

***N,N*-diallyl-3-iodoaniline (4c)**



Yield = 75%. Yellow oil. **R_f** = 0.24 (hexane). **^1H NMR** (400 MHz, CDCl_3): δ = 3.88 (dt, J = 4.7, 1.7 Hz, 4H), 5.16 (dq, J = 17.5, 1.7 Hz, 2H), 5.17 (dq, J = 10.0, 1.7 Hz, 2H), 5.82 (ddt, J = 17.5, 10.0, 4.7 Hz, 2H), 6.63 (ddd, J = 8.2, 2.5, 0.8 Hz, 1H), 6.88 (t, J = 8.2 Hz, 1H), 6.97–7.01 (m, 1H), 6.99–7.01 (m, 1H). **^{13}C NMR** (100.6 MHz, CDCl_3): δ = 52.6, 95.4, 111.5, 116.3, 120.9, 125.1, 130.4, 133.2, 149.8. **MS** (ESI): m/z (%) = 299.6 ($[\text{M}+\text{H}]^+$, 100). **HRMS** (ESI): calculated for $\text{C}_{12}\text{H}_{15}\text{IN}$ ($[\text{M}+\text{H}]^+$) 300.0244; found 300.0254. **MW** = 299.16. ^1H NMR spectrum and ^{13}C NMR spectrum are provided in Figures S6–S7.


1.4. Synthesis of tris(3,5-dimethyl-1*H*-pyrazol-1-yl)methane (**S5**)



Tris(3,5-dimethyl-1*H*-pyrazol-1-yl)methane (**S5**) was synthesized *via* a procedure reported by Reger et al.⁵


In a bulb of 1 L containing 500 mL of demineralized water, 48.1 g of 3,5-dimethylpyrazole (**S4**) (500 mmol, 1 equiv) and 8.06 g of tetra-*n*-butylammonium bromide (25.0 mmol, 0.05 equiv) were brought together. With vigorous mechanical stirring, 318 g of sodium carbonate (3.00 mol, 6 equiv) was added gradually to the reaction mixture. After cooling to room temperature, 250 mL of chloroform was added and the mixture was refluxed for 3 days during which an orange-red emulsion had formed. Next, the solids were filtered off on a sintered glass Büchner funnel and the filter cake was rinsed with chloroform until the filtrate turned colorless. The organic and aqueous layers in the filtrate were separated. The organic layer was washed with an equal volume of brine and dried over magnesium sulfate. Evaporation *in vacuo* afforded a dark brown solid (60.6 g) which was recrystallized from absolute ethanol to give tris(3,5-dimethyl-1*H*-pyrazol-1-yl)methane (**S5**) (19.2 g, 39%) as an off-white powder.

Tris(3,5-dimethyl-1*H*-pyrazol-1-yl)methane (S5**)**^{6,7}



Yield = 39%. Off-white powder (from absolute ethanol). **¹H NMR** (400 MHz, CDCl₃): δ = 2.01 (br. s, 9H), 2.18 (s, 9H), 5.88 (s, 3H), 8.07 (s, 1H). **MW** = 298.39. **¹H NMR** spectrum is provided in Figure S8.

1.5. General procedure for the *N*-arylation of 2-pyrrolidinone with aryl iodides




The preparation of pyrrolidinones **6a,b,d** was adopted from Haldón et al.⁸

In a flame-dried bulb of 250 mL containing 100 mL of dry 1,4-dioxane, 0.952 g of CuI (5.00 mmol, 0.05 equiv) and 1.49 g of tris(3,5-dimethyl-1*H*-pyrazol-1-yl)methane (**S5**) (5.00 mmol, 0.05 equiv) were brought together under a nitrogen atmosphere. Then, aryl iodide (100 mmol, 1 equiv), 9.12 mL of 2-pyrrolidinone (120 mmol, 1.2 equiv) and 42.4 g of K₃PO₄ (200 mmol, 2 equiv) were added and the reaction mixture was stirred at reflux temperature for 24 hours. A beige suspension was formed during this step. Next, the suspension was cooled down to room temperature and the solids were filtered off on a sintered glass Büchner funnel. The filter cake was rinsed with ethyl acetate until the filtrate turned colorless. The filtrate was washed with an equal volume of 3 M aqueous HCl (3×) and brine, after which the organic layer was dried over magnesium sulfate and evaporated *in vacuo*.

1.5.1. Synthesis of pyrrolidinone **6a**

Pyrrolidinone **6a** was synthesized from aryl iodide **4a** (11.2 mL, 100 mmol, 1 equiv) and 2-pyrrolidinone (9.12 mL, 120 mmol, 1.2 equiv). Evaporation *in vacuo* afforded pyrrolidinone **6a** (14.3 g, 89%) as beige fibers. An analytical sample was prepared by recrystallization from absolute ethanol.

1-Phenylpyrrolidin-2-one (**6a**)^{9,10}




Yield = 89%. Beige fibers. ¹H NMR (400 MHz, CDCl₃): δ = 2.16 (p, *J* = 7.6 Hz, 2H), 2.61 (t, *J* = 7.6 Hz, 2H), 3.87 (t, *J* = 7.6 Hz, 2H), 7.11–7.17 (m, 1H), 7.33–7.40 (m, 2H), 7.58–7.64 (m, 2H). **MW** = 161.20. ¹H NMR spectrum is provided in Figure S9.

1.5.2. Synthesis of pyrrolidinone **6b**

Pyrrolidinone **6b** was synthesized from aryl iodide **4b** (45.0 g, 173 mmol, 1 equiv) and 2-pyrrolidinone (15.8 mL, 208 mmol, 1.2 equiv). Evaporation *in vacuo* afforded a red oil (38.9 g) which was further purified *via* automated flash chromatography with hexane/ethyl acetate as eluent. Half of the crude mixture was manually injected on a

Reveleris® 120 g silica cartridge (16% sample loading) and the injection valve was subsequently rinsed twice with 5 mL of the initial mobile phase (flow rate: 80 mL min⁻¹; eluent: 2 column volumes (CV) of 12% ethyl acetate, followed by a gradient from 12% to 100% ethyl acetate over 10 CV and finally 2 CV of 100% ethyl acetate; detection wavelengths: 254 nm and 268 nm). Next, the same conditions were applied to purify the other half of the crude mixture and evaporation of the combined fractions yielded pyrrolidinone **6b** (28.2 g, 75%) as a yellow-orange oil.

1-(3-(Allyloxy)phenyl)pyrrolidin-2-one (**6b**)




Yield = 75%. Yellow-orange oil. **R_f** = 0.51 (ethyl acetate). **¹H NMR** (400 MHz, CDCl₃): δ = 2.15 (p, *J* = 7.6 Hz, 2H), 2.61 (t, *J* = 7.6 Hz, 2H), 3.84 (t, *J* = 7.6 Hz, 2H), 4.55 (dt, *J* = 5.3, 1.4 Hz, 2H), 5.29 (dq, *J* = 10.6, 1.4 Hz, 1H), 5.42 (dq, *J* = 17.3, 1.4 Hz, 1H), 6.06 (ddt, *J* = 17.3, 10.6, 5.3 Hz, 1H), 6.71 (ddd, *J* = 8.2, 2.2, 0.7 Hz, 1H), 7.13 (ddd, *J* = 8.2, 2.2, 0.7 Hz, 1H), 7.25 (t, *J* = 8.2 Hz, 1H), 7.37 (t, *J* = 2.2 Hz, 1H). **¹³C NMR** (100.6 MHz, CDCl₃): δ = 18.0, 32.9, 48.9, 68.9, 106.8, 110.8, 112.1, 117.8, 129.5, 133.2, 140.6, 158.9, 174.3. **MS** (ESI): *m/z* (%) = 218.1 ([M+H]⁺, 100). **HRMS** (ESI): calculated for C₁₃H₁₆NO₂ ([M+H]⁺) 218.1176; found 218.1178. **MW** = 217.26. ¹H NMR spectrum and ¹³C NMR spectrum are provided in Figures S10–S11.

1.5.3. Synthesis of pyrrolidinone **6d**


Pyrrolidinone **6d** was synthesized from aryl iodide **4d** (28.5 g, 124 mmol, 1 equiv) and 2-pyrrolidinone (11.3 mL, 149 mmol, 1.2 equiv). Evaporation *in vacuo* afforded pyrrolidinone **6d** (20.4 g, 88%) as beige crystals. An analytical sample was prepared by recrystallization from absolute ethanol.

3-(2-Oxopyrrolidin-1-yl)benzonitrile (**6d**)¹¹



Yield = 88%. Beige crystals (mp 83 °C). **¹H NMR** (400 MHz, CDCl₃): δ = 2.21 (p, *J* = 7.6 Hz, 2H), 2.64 (t, *J* = 7.6 Hz, 2H), 3.87 (t, *J* = 7.6 Hz, 2H), 7.40 (dt, *J* = 8.0, 1.3 Hz, 1H), 7.46 (t, *J* = 8.0 Hz, 1H), 7.91 (ddd, *J* = 8.0, 2.3, 1.3 Hz, 1H), 7.96–7.99 (m, 1H). **¹³C NMR** (100.6 MHz, CDCl₃): δ = 17.8, 32.6, 48.3, 112.9, 118.6, 122.5, 123.5, 127.6, 129.7, 140.2, 175.6. **MS** (ESI): *m/z* (%) = 186.9 ([M+H]⁺, 100). **HRMS** (ESI): calculated for C₁₁H₁₁N₂O ([M+H]⁺) 187.0866; found 187.0860. **MW** = 186.21. ¹H NMR spectrum and ¹³C NMR spectrum are provided in Figures S12–S13.


1.6. Synthesis of pyrrolidinone 6c



For the synthesis of pyrrolidinone **6c**, the general procedure for the *N*-arylation of 2-pyrrolidinone with aryl iodides was slightly modified.

In a flame-dried bulb of 250 mL containing 96 mL of dry 1,4-dioxane, 0.909 g of CuI (4.76 mmol, 0.05 equiv) and 1.42 g of tris(3,5-dimethyl-1*H*-pyrazol-1-yl)methane (**S5**) (4.76 mmol, 0.05 equiv) were brought together under a nitrogen atmosphere. Then, 28.5 g of aryl iodide **4c** (95.3 mmol, 1 equiv), 8.68 mL of 2-pyrrolidinone (114 mmol, 1.2 equiv) and 40.5 g of K₃PO₄ (191 mmol, 2 equiv) were added under a nitrogen atmosphere and the reaction mixture was stirred under reflux for 24 hours. Next, a second portion of CuI (0.909 g, 4.76 mmol, 0.05 equiv) and of tris(3,5-dimethyl-1*H*-pyrazol-1-yl)methane (**S6**) (1.42 g, 4.76 mmol, 0.05 equiv) were added and the reaction mixture was refluxed for 24 hours. Afterwards, a third portion of CuI (0.909 g, 4.76 mmol, 0.05 equiv) and of tris(3,5-dimethyl-1*H*-pyrazol-1-yl)methane (**S6**) (1.42 g, 4.76 mmol, 0.05 equiv) were added and the mixture was stirred for another 24 hours at reflux temperature. A beige suspension was formed during this reaction. After cooling to room temperature, the solids were filtered off on a sintered glass Büchner funnel and the filter cake was rinsed with ethyl acetate until the filtrate turned colorless. The filtrate was washed with an equal volume of saturated aqueous NH₄Cl (3×) and brine, after which the organic layer was isolated and dried with magnesium sulfate. Evaporation *in vacuo* afforded an orange-red oil (32.5 g) of which 5.41 g was dissolved in acetonitrile and coated under reduced pressure onto 10.8 g of Davisil® C18 silica. Subsequently, purification was performed *via* automated flash chromatography with water/acetonitrile as eluent on a Reveleris® 120 g C18 cartridge (5% sample loading; flow rate: 80 mL min⁻¹; eluent: 2 CV of 20% acetonitrile, followed by a gradient from 20% to 40% acetonitrile over 30 CV and finally a gradient from 40% to 100% acetonitrile over 20 CV; detection wavelengths: 222 nm and 262 nm). Next, the same conditions were repeated another 5 times to purify the remaining parts of the crude mixture. Coevaporation of the combined fractions with chloroform, to remove traces of water, resulted in pyrrolidinone **6c** (19.3 g, 79%) as a yellow-orange oil.


1-(3-(Diallylamino)phenyl)pyrrolidin-2-one (**6c**)



Yield = 79%. Yellow oil. *R*_f = 0.27 (hexane/ethyl acetate, 3:2). ¹H NMR (400 MHz, CDCl₃): δ = 2.12 (p, *J* = 7.6 Hz, 2H), 2.58 (t, *J* = 7.6 Hz, 2H), 3.83 (t, *J* = 7.6 Hz, 2H),

3.93 (dt, $J=4.9, 1.7$ Hz, 4H), 5.16 (dq, $J=9.3, 1.7$ Hz, 2H), 5.19 (dq, $J=16.3, 1.7$ Hz, 2H), 5.85 (ddt, $J=16.3, 9.3, 4.9$ Hz, 2H), 6.47–6.52 (m, 1H), 6.75 (ddd, $J=8.1, 2.1, 0.6$ Hz, 1H), 7.16 (t, $J=8.1$ Hz, 1H), 7.16 (t, $J=2.1$ Hz, 1H). **^{13}C NMR** (100.6 MHz, CDCl_3): $\delta = 18.1, 32.9, 49.1, 52.9, 104.7, 108.0, 108.9, 116.1, 129.2, 133.9, 140.3, 149.2, 174.1$. **MS** (ESI): m/z (%) = 256.8 ($[\text{M}+\text{H}]^+$, 100). **HRMS** (ESI): calculated for $\text{C}_{16}\text{H}_{21}\text{N}_2\text{O}$ ($[\text{M}+\text{H}]^+$) 257.1648; found 257.1647. **MW** = 256.35. ^1H NMR spectrum and ^{13}C NMR spectrum are provided in Figures S14–S15.


1.7. Synthesis of pyrrolidinethione 10



In a flame-dried bulb of 100 mL containing 50 mL of dry tetrahydrofuran, 1.86 g of pyrrolidinone **6d** (1.00 mmol, 1 equiv) and 2.00 g of Lawesson's reagent **S6** (0.500 mmol, 0.5 equiv) were brought together under a nitrogen atmosphere and stirred for 30 minutes at reflux temperature. Then, the reaction mixture was cooled to 0 °C, diluted with 50 mL of diethyl ether and the resulting slurry was filtered off over celite. Evaporation of the filtrate *in vacuo* afforded a yellow solid (3.70 g) which was dissolved in toluene and coated under reduced pressure onto 14.8 g of silica. Subsequently, purification was performed *via* automated flash chromatography with hexane/ethyl acetate as eluent on a Reveleris® 80 g silica cartridge (5% sample loading; flow rate: 60 mL min⁻¹; eluent: 2 CV of 0% ethyl acetate, followed by a gradient from 0% to 30% ethyl acetate over 60 CV and finally 5 CV of 100% ethyl acetate; detection wavelength: 272 nm). This afforded pyrrolidinethione **10** (1.60 g, 79%) as off-white fibers.

When excess Lawesson's reagent **S6** (more than 0.5 equivalents) and/or prolonged reaction times (more than 30 minutes) were used at elevated temperatures (70 °C), thionation of the nitrile functionality in pyrrolidinethione **10** also occurred, resulting in side product **S8**. Moreover, it should be noted it is crucial to use toluene to dissolve the crude product prior to flash chromatography: in order to obtain a high yield and good separation between desired product **10**, Lawesson's reagent byproduct **S7** and thiobenzamide **S8** during chromatography, it is important to obtain a free-flowing, well-coated mixture. From an extensive series of solvents (toluene, ethyl acetate, acetone, tetrahydrofuran, dichloromethane, chloroform, methanol and acetonitrile), toluene was the only solvent able to do so.


3-(2-Thioxopyrrolidin-1-yl)benzonitrile (**10**)



Yield = 79%. Off-white fibers (mp 132 °C). ¹H NMR (400 MHz, CDCl₃): δ = 2.27 (p, *J* = 7.5 Hz, 2H), 3.24 (t, *J* = 7.5 Hz, 2H), 4.15 (t, *J* = 7.5 Hz, 2H), 7.53–7.63 (m, 2H), 7.87–7.92 (m, 2H). ¹³C NMR (100.6 MHz, CDCl₃): δ = 20.7, 46.4, 58.1, 113.2, 117.9, 128.3, 129.4, 130.0,

130.9, 141.2, 204.0. **MS** (ESI): m/z (%) = 203.2 ($[M+H]^+$, 100). **MW** = 202.28. ^1H NMR spectrum and ^{13}C NMR spectrum are provided in Figures S16–S17.


1.8. Synthesis of methyl 2-amino-5-methylbenzoate (**7**)



The preparation of methyl 2-amino-5-methylbenzoate (**7**) was adopted from Lawson et al.¹²


To a solution of 30.5 g of 2-amino-5-methylbenzoic acid (**S9**) (184 mmol, 1 equiv) in 500 mL of methanol, 30 mL of concentrated H₂SO₄ was added and the resulting mixture was stirred at reflux temperature for 3 days. After cooling to room temperature, the solvent was removed *in vacuo*. The yellow residue was taken up in 250 mL of ethyl acetate and washed subsequently with an equal volume of 1 M aqueous NaOH. The organic layer was dried over magnesium sulfate and evaporated *in vacuo* to afford methyl 2-amino-5-methylbenzoate (**7**) (31.0 g, quant.) as a beige-orange powder.

Methyl 2-amino-5-methylbenzoate (**7**)^{13,14}



Yield = quant. Beige-orange powder. **¹H NMR** (400 MHz, CDCl₃): δ = 2.22 (s, 3H), 3.85 (s, 3H), 5.53 (br. s, 2H), 6.59 (d, J = 8.3 Hz, 1H), 7.09 (dd, J = 8.3, 2.2 Hz, 1H), 7.66 (d, J = 2.2 Hz, 1H). **MW** = 165.19. ¹H NMR spectrum is provided in Figure S18.

1.9. General procedure for the synthesis of amidines from pyrrolidinones




The synthesis of amidines **8a,b,d** from pyrrolidinones **6a,b,d** was performed *via* a modified procedure of Lucas-Lopez et al.¹⁵

A flame-dried bulb of 100 mL, kept under a nitrogen atmosphere, was loaded with 40 mL of dry dichloromethane and pyrrolidinone (15.0 mmol, 1 equiv). Next, 2.80 mL of POCl_3 (30.0 mmol, 2 equiv) was added and the resulting mixture was stirred at room temperature for 24 hours. Afterwards, a solution of methyl 2-amino-5-methylbenzoate (**7**) (2.60 g, 15.8 mmol, 1.05 equiv) in dry dichloromethane (15 mL) was added *via* syringe and the reaction mixture was heated to 35 °C for 24 hours. Then, the reaction mixture was cooled to 0 °C, basified with 3 M aqueous NaOH until the pH equaled 10, and subsequently extracted with an equal volume of ethyl acetate (3×). The combined organic layers were washed with an equal volume of brine, dried over magnesium sulfate and evaporated *in vacuo*.

1.9.1. Synthesis of amidine **8a**

Amidine **8a** was synthesized from pyrrolidinone **6a** (2.42 g, 15.0 mmol, 1 equiv) and methyl 2-amino-5-methylbenzoate (**7**) (2.60 g, 15.8 mmol, 1.05 equiv). Evaporation *in vacuo* afforded an orange-brown oil (5.71 g) which was dissolved in acetonitrile/dichloromethane (1:1) and coated under reduced pressure onto 11.4 g of Davisil® C18 silica. Subsequently, purification was performed *via* automated flash chromatography with water/acetonitrile as eluent on a Reveleris® 120 g C18 cartridge (5% sample loading; flow rate: 80 mL min⁻¹; eluent: 2 CV of 30% acetonitrile, followed by a gradient from 30% to 100% acetonitrile over 20 CV and finally 2 CV of 100% acetonitrile; detection wavelengths: 218 nm and 246 nm). Coevaporation with chloroform, to remove traces of water, afforded amidine **8a** (3.90 g, 78%) as an off-white powder. An analytical sample was prepared by recrystallization from absolute ethanol.

Methyl 5-methyl-2-((1-phenylpyrrolidin-2-ylidene)amino)benzoate (**8a**)¹⁵




Yield = 78%. Off-white powder. ¹H NMR (400 MHz, CDCl_3): δ = 2.03 (p, J = 7.3 Hz, 2H), 2.31 (s, 3H), 2.46 (t, J = 7.3 Hz, 2H), 3.81 (s, 3H), 3.87 (t, J = 7.3 Hz, 2H), 6.71 (d, J = 8.1 Hz, 1H), 7.02–7.08 (m, 1H), 7.18 (dd, J = 8.1, 1.7 Hz, 1H), 7.31–7.38 (m, 2H),

7.65 (d, $J = 1.7$ Hz, 1H), 7.79–7.84 (m, 2H). **MW** = 308.37. ^1H NMR spectrum is provided in Figure S19.

1.9.2. Synthesis of amidine 8b

Amidine **8b** was synthesized from pyrrolidinone **6b** (26.5 g, 122 mmol, 1 equiv) and methyl 2-amino-5-methylbenzoate (**7**) (21.1 g, 128 mmol, 1.05 equiv). Evaporation *in vacuo* afforded an orange-brown oil (42.9 g) of which 14.3 g was dissolved in dichloromethane and coated under reduced pressure onto 28.6 g of silica. Subsequently, purification was performed *via* automated flash chromatography with hexane/ethyl acetate/triethylamine as eluent on a Reveleris® 120 g silica cartridge (12% sample loading; flow rate: 80 mL min⁻¹; eluent: 2 CV of a 7% ethyl acetate/triethylamine mixture (ethyl acetate + 16% triethylamine), followed by a gradient from 7% to 60% ethyl acetate/triethylamine mixture over 10 CV and finally 3 CV of a 60% ethyl acetate/triethylamine mixture; detection wavelengths: 246 nm and 298 nm). Next, the same conditions were repeated twice to purify the remaining parts of the crude mixture. Evaporation of the combined fractions afforded amidine **8b** (22.2 g, 50%) as a light yellow powder.

Methyl 2-((1-(3-(allyloxy)phenyl)pyrrolidin-2-ylidene)amino)-5-methylbenzoate (**8b**)




Yield = 50%. Light yellow powder (mp 66 °C). R_f = 0.42 (hexane/ethyl acetate/triethylamine, 7:3:0.5). ^1H NMR (400 MHz, CDCl_3): δ = 2.03 (p, $J = 7.3$ Hz, 2H), 2.32 (s, 3H), 2.46 (t, $J = 7.3$ Hz, 2H), 3.83 (s, 3H), 3.85 (t, $J = 7.3$ Hz, 2H), 4.53 (dt, $J = 5.4, 1.4$ Hz, 2H), 5.25 (dq, $J = 10.6, 1.4$ Hz, 1H), 5.39 (dq, $J = 17.2, 1.4$ Hz, 1H), 6.05 (ddt, $J = 17.2, 10.6, 5.4$ Hz, 1H), 6.62 (ddd, $J = 8.1, 2.2, 0.8$ Hz, 1H), 6.70 (d, $J = 8.1$ Hz, 1H), 7.18 (dd, $J = 8.1, 1.8$ Hz, 1H), 7.22 (t, $J = 8.1$ Hz, 1H), 7.30 (ddd, $J = 8.1, 2.2, 0.8$ Hz, 1H), 7.65 (d, $J = 1.8$ Hz, 1H), 7.67 (t, $J = 2.2$ Hz, 1H). ^{13}C NMR (100.6 MHz, CDCl_3): δ = 19.7, 20.6, 29.2, 50.7, 51.7, 68.8, 107.3, 109.4, 112.6, 117.7, 121.9, 122.9, 129.2, 131.0, 133.5, 133.5, 142.7, 150.6, 158.8, 159.7, 167.8. **MS** (ESI): m/z (%) = 364.6 ($[\text{M}+\text{H}]^+$, 100). **HRMS** (ESI): calculated for $\text{C}_{22}\text{H}_{25}\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$) 365.1860; found 365.1848. **MW** = 364.44. ^1H NMR spectrum and ^{13}C NMR spectrum are provided in Figures S20–S21.

1.9.3. Synthesis of amidine 8d

Amidine **8d** was synthesized from pyrrolidinone **6d** (20.8 g, 112 mmol, 1 equiv) and methyl 2-amino-5-methylbenzoate (**7**) (19.4 g, 117 mmol, 1.05 equiv). Evaporation *in vacuo* afforded a red-brown oil (38.8 g) of which 6.47 g was dissolved in acetonitrile/dichloromethane (1:1) and coated under reduced pressure onto 12.9 g of Davisil® C18 silica. Subsequently, purification was performed *via* automated flash chromatography with water/acetonitrile as eluent on a Reveleris® 120 g C18 cartridge (5% sample loading; flow rate: 80 mL min⁻¹; eluent: 2 CV of 30% acetonitrile, followed by a gradient from 30% to 100% acetonitrile over 20 CV and finally 2 CV of 100% acetonitrile; detection wavelengths: 216 nm and 274 nm). Next, the same conditions were repeated


another 5 times to purify the remaining parts of the crude mixture. Coevaporation of the combined fractions with chloroform, to remove traces of water, yielded amidine **8d** (11.2 g, 30%) as an off-white powder.

Methyl 2-((1-(3-cyanophenyl)pyrrolidin-2-ylidene)amino)-5-methylbenzoate (8d**)**



Yield = 30%. Off-white powder (mp 116 °C). R_f = 0.32 (hexane/ethyl acetate/triethylamine, 7:3:0.5). **^1H NMR** (400 MHz, CDCl_3): δ = 2.08 (p, J = 7.4 Hz, 2H), 2.33 (s, 3H), 2.49 (t, J = 7.4 Hz, 2H), 3.82 (s, 3H), 3.86 (t, J = 7.4 Hz, 2H), 6.69 (d, J = 8.1 Hz, 1H), 7.21 (dd, J = 8.1, 1.6 Hz, 1H), 7.31 (dt, J = 7.8, 1.3 Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.69 (d, J = 1.6 Hz, 1H), 8.08–8.17 (m, 1H), 8.21 (t, J = 1.3 Hz, 1H). **^{13}C NMR** (100.6 MHz, CDCl_3): δ = 19.6, 20.6, 29.0, 50.2, 51.8, 112.4, 119.2, 121.2, 122.5, 123.0, 124.0, 125.9, 129.4, 131.2, 131.6, 133.7, 142.2, 149.8, 159.8, 167.4. **MS** (ESI): m/z (%) = 333.6 ($[\text{M}+\text{H}]^+$, 100). **HRMS** (ESI): calculated for $\text{C}_{20}\text{H}_{20}\text{N}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$) 334.1550; found 334.1543. **MW** = 333.38. ^1H NMR spectrum and ^{13}C NMR spectrum are provided in Figures S22–S23.

1.10. General procedure for the synthesis of quinolones from amidines




The synthesis of quinolones **9a**, **9b**, **9d** from amidines **8a**, **8b**, **8d** was performed *via* a modified procedure of Lawson et al.¹²

A flame-dried bulb of 100 mL, kept under a nitrogen atmosphere, was loaded with 15 mL of dry tetrahydrofuran and amidine (14.7 mmol, 1 equiv). Then, the solution was cooled to -78 °C and 36.8 mL of lithiumbis(trimethylsilyl)amide (1 M solution in tetrahydrofuran, 36.8 mmol, 2.5 equiv) was added. Subsequently, the mixture was stirred at 0 °C for 1 hour before being quenched by the addition of 60 mL of saturated aqueous NH₄Cl. The layers were separated and the organic layer was washed with an equal volume of saturated aqueous NH₄Cl (2×) and concentrated *in vacuo* to approximately 10 mL. Next, the residue was diluted with 75 mL of ethyl acetate, dried over magnesium sulfate and evaporated *in vacuo*.

1.10.1. Synthesis of quinolone **9a**

Quinolone **9a** was synthesized from amidine **8a** (4.54 g, 14.7 mmol, 1 equiv). Evaporation *in vacuo* gave a yellow-orange powder which was washed on a sintered glass Büchner funnel with ice cold ethyl acetate until the filtrate turned colorless. This afforded quinolone **9a** (3.98 g, 98%) as a beige powder.

6-Methyl-1-phenyl-1,2,3,9-tetrahydro-4*H*-pyrrolo[2,3-*b*]quinolin-4-one (**9a**)¹⁵




Yield = 98%. Beige powder. ¹H NMR (400 MHz, DMSO-*d*⁶): δ = 2.41 (s, 3H), 3.17 (t, *J* = 7.9 Hz, 2H), 4.07 (t, *J* = 7.9 Hz, 2H), 7.01 (t, *J* = 7.2 Hz, 1H), 7.32 (dd, *J* = 8.4, 1.8 Hz, 1H), 7.39 (t, *J* = 7.2 Hz, 2H), 7.51 (d, *J* = 8.4 Hz, 1H), 7.77 (br. s, 1H), 8.05 (br. s, 2H), 10.46 (br. s, 1H). **MW** = 276.33. ¹H NMR spectrum is provided in Figure S24.

1.10.2. Synthesis of quinolone 9b

Quinolone **9b** was prepared from amidine **8b** (19.9 g, 54.6 mmol, 1 equiv). Evaporation *in vacuo* resulted in an orange powder (18.7 g) which was washed on a sintered glass Büchner funnel with ice cold ethyl acetate until the filtrate turned colorless. This afforded quinolone **8b** (15.0 g, 82%) as an off-white powder.

1-(3-(Allyloxy)phenyl)-6-methyl-1,2,3,9-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-one (9b)



Yield = 82%. Off-white powder (mp 203 °C). R_f = 0.13 (ethyl acetate).

^1H NMR (400 MHz, DMSO- d_6): δ = 2.42 (s, 3H), 3.17 (t, J = 7.9 Hz, 2H), 4.06 (t, J = 7.9 Hz, 2H), 4.63 (dt, J = 5.2, 1.5 Hz, 2H), 5.29 (dq, J = 10.6, 1.5 Hz, 1H), 5.46 (dq, J = 17.2, 1.5 Hz, 1H), 6.11 (ddt, J = 17.2, 10.6, 5.2 Hz, 1H), 6.60 (d, J = 7.7 Hz, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.32 (dd, J = 8.4,

1.5 Hz, 1H), 7.45 (d, J = 7.7 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.77 (br. s, 1H), 8.04 (br. s, 1H), 10.46 (br. s, 1H).


^{13}C NMR (100.6 MHz, DMSO- d_6): δ = 21.5, 22.3, 48.6, 68.6, 104.5, 106.9, 107.5, 110.0, 117.9, 119.1, 121.0, 126.7, 129.6, 130.8, 131.2, 134.4, 143.8, 146.8, 154.2, 158.9, 159.8. **MS** (ESI): m/z (%) = 332.7 ($[\text{M}+\text{H}]^+$, 100).

HRMS (ESI): calculated for $\text{C}_{21}\text{H}_{21}\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$) 333.1598; found 333.1604. **MW** = 332.40. ^1H NMR spectrum and ^{13}C NMR spectrum are provided in Figures S25–S26.

1.10.3. Synthesis of quinolone 9d

Quinolone **9d** was obtained from amidine **8d** (10.8 g, 30.9 mmol, 1 equiv). Evaporation *in vacuo* resulted in an ochreous powder (12.3 g) which was washed on a sintered glass Büchner funnel with ice cold ethyl acetate until the filtrate turned colorless. This afforded quinolone **9d** (8.01 g, 86%) as a beige powder.

3-(6-Methyl-4-oxo-2,3,4,9-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-yl)benzonitrile (9d)




Yield = 86%. Beige powder (mp 252 °C). **^1H NMR** (400 MHz, DMSO- d_6): δ = 2.43 (s, 3H), 3.20 (t, J = 7.6 Hz, 2H), 4.10 (t, J = 7.6 Hz, 2H), 7.36 (d, J = 8.2 Hz, 1H), 7.41 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 7.58 (t, J = 7.9 Hz, 1H), 7.80 (br. s, 1H), 8.39 (d, J = 7.9 Hz, 1H), 8.62 (br. s, 1H), 10.63 (br. s, 1H). **^{13}C NMR** (100.6 MHz, DMSO- d_6): δ = 21.5, 22.3, 48.4, 106.8, 111.8,

119.2, 119.8, 120.1, 121.0, 121.8, 124.1, 126.8, 130.3, 131.1, 131.8, 143.2, 146.5, 154.7, 159.4. **MS** (ESI): m/z (%) = 301.7 ($[\text{M}+\text{H}]^+$, 100). **HRMS** (ESI): calculated for $\text{C}_{19}\text{H}_{16}\text{N}_3\text{O}$ ($[\text{M}+\text{H}]^+$) 302.1288; found 302.1296.

MW = 301.34. ^1H NMR spectrum and ^{13}C NMR spectrum are provided in Figures S27–S28.

1.11. Synthesis of (*S*)-3'-diallylaminoblebbistatin ((*S*)-12) and (*S*)-3'-diallylaminoblebbistatin ((*S*)-12)



- (a) i) 2 equiv POCl₃, dry CH₂Cl₂, rt, 24 h, N₂; ii) 1.05 equiv **7**, dry CH₂Cl₂, 35 °C, 24 h, N₂
 (b) 2.5 equiv LiHMDS, dry THF, 0 °C, 1 h, N₂
 (c) i) 1.2 equiv LiHMDS, dry THF, -78 °C, 30 min, Ar;
 ii) 2.4 equiv **14** (for (*S*)-12) or **15** (for (*R*)-12), dry THF, -15 °C, 16 h, Ar


Amidine **8c** was obtained from pyrrolidinone **6c** (24.6 g, 96.0 mmol, 1 equiv) and methyl 2-amino-5-methylbenzoate (**7**) (16.7 g, 101 mmol, 1.05 equiv) *via* the general procedure for the synthesis of amidines from pyrrolidinones. During aqueous work-up, part of the amidine **8c** was converted into side product **S10** due to hydrolysis of the amidine functionality. Evaporation *in vacuo* afforded a red-brown oil (39.0 g) of which 6.50 g was dissolved in acetonitrile/dichloromethane (1:1) and coated under reduced pressure onto 13.0 g of Davisil® C18 silica. Subsequently, purification was performed *via* automated flash chromatography with water/acetonitrile as eluent on a Reveleris® 120 g C18 cartridge (5% sample loading; flow rate: 80 mL min⁻¹; eluent: 2 CV of 40% acetonitrile, a gradient from 40% to 80% acetonitrile over 20 CV, 4 CV of 80% acetonitrile and finally 3 CV of 100% acetonitrile; detection wavelengths: 256 nm and 330 nm). Next, the same conditions were repeated another 5 times to purify the remaining parts of the crude mixture. Coevaporation of the combined fractions with chloroform, to remove traces of water, resulted in crude amidine **8c** as a red-brown oil (11.9 g) that still contained side product **S10** as impurity.

Quinolone **9c** was synthesized from the crude amidine **8c** (8.69 g, 21.5 mmol, 1 equiv) *via* the general procedure for the synthesis of quinolones from amidines. Evaporation *in vacuo* resulted in a red oil (8.83 g) which was dissolved in tetrahydrofuran and coated under reduced pressure onto 26.5 g of silica. Subsequently, purification was performed *via* automated flash chromatography with hexane/ethyl acetate/methanol as eluent on a Reveleris® 80 g silica cartridge (11% sample loading; flow rate: 60 mL min⁻¹; eluent: 2 CV of 50% ethyl acetate, a gradient from 50% to 100% ethyl acetate over 10 CV, 5 CV of 100% ethyl acetate and finally 25 CV of a 10% methanol/90% ethyl acetate; detection wavelengths: 256 nm and 334 nm). Evaporation resulted in crude quinolone **9c** as an orange oil (4.97 g) that still contained side product **S11** (formed out of side product **S10** during reaction) as impurity.

Synthesis of (*S*)-3'-diallylaminoblebbistatin (*S*)-**12**

(*S*)-3'-diallylaminoblebbistatin (*S*)-**12** was synthesized from the crude quinolone **9c** (3.96 g, 10.7 mmol, 1 equiv) *via* the general procedure for the asymmetric α -hydroxylation of quinolones and using Davis' oxaziridine **14** (7.64 g, 25.6 mmol, 2.4 equiv). Evaporation *in vacuo* resulted in (*S*)-**12** (3.02 g, 73%) as an orange powder. The enantiomeric excess was 76% as determined by chiral HPLC analysis (Daicel Chiralpak IA column, acetonitrile/water (45:55), 1.0 mL min⁻¹, 25 °C). The powder was redissolved in 60 mL of boiling absolute ethanol and left untouched for 1 hour at room temperature. After 40 minutes fibers had formed, which were filtered off after an additional 20 minutes. This resulted in (*S*)-3'-diallylaminoblebbistatin (*S*)-**12** (1.03 g, 25%) as bright orange cotton-like fibers with an enantiomeric excess of >99%.

(*S*)-1-(3-(diallylamino)phenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4*H*-pyrrolo[2,3-*b*]quinolin-4-one ((*S*)-**12**)




Yield = 25%. Bright orange, cotton-like fibers (from absolute ethanol, mp 167 °C). **ee** >99%, chiral HPLC: t_R ((*S*)-**11**) = 27.1 min, t_R ((*R*)-**11**) = 31.1 min (Daicel Chiralpak IA column, acetonitrile/water (45:55), 1.0 mL min⁻¹, 25 °C). $[\alpha]_D^{25} = -248 \pm 2$ ($c = 0.11$ in tetrahydrofuran). **¹H NMR** (400 MHz, DMSO-*d*₆): δ = 2.19–2.27 (m, 2H), 2.30 (s, 3H), 3.87–3.95 (m, 1H), 3.94–4.07 (m, 5H), 3.12–5.24 (m, 4H), 5.92 (ddt, $J = 17.1$, 10.2, 5.1 Hz, 2H), 6.47 (dd, $J = 8.1$, 2.0 Hz, 1H), 6.79 (s, 1H), 6.98 (dd, $J = 8.1$, 2.0 Hz, 1H), 7.07 (d, $J = 8.1$ Hz, 1H), 7.15 (t, $J = 8.1$ Hz, 1H), 7.38 (dd, $J = 8.1$, 1.8 Hz, 1H), 7.52 (d, $J = 1.8$ Hz, 1H), 7.94 (t, $J = 2.0$ Hz, 1H). **¹³C NMR** (100.6 MHz, DMSO-*d*₆): δ = 20.7, 28.8, 47.9, 53.0, 73.5, 104.8, 107.4, 108.3, 116.4, 121.4, 126.2, 126.8, 129.4, 132.5, 134.8, 137.0, 141.9, 148.9, 149.8, 165.7, 195.1. **MS** (ESI): m/z (%) = 387.5 ($[M+H]^+$, 100). **HRMS** (ESI): calculated for C₂₄H₂₆N₃O₂ ($[M+H]^+$) 388.2020; found 388.2035. **MW** = 387.47. ¹H NMR spectrum, ¹³C NMR spectrum and chiral HPLC chromatograms are provided in Figures S35–S36 and Figures S57–S58.

Synthesis of (*R*)-3'-diallylaminoblebbistatin (*R*)-12

(*R*)-3'-diallylaminoblebbistatin (*R*)-12 was synthesized from the crude quinolone **9c** (0.967 g, 2.60 mmol, 1 equiv) *via* the general procedure for the asymmetric α -hydroxylation of quinolones and using Davis' oxaziridine **15** (1.86 g, 6.24 mmol, 2.4 equiv). Evaporation *in vacuo* resulted in (*R*)-3'-diallylaminoblebbistatin (*R*)-12 (0.686 g, 68%) as an orange powder. The enantiomeric excess was 74% as determined by chiral HPLC analysis (Daicel Chiralpak IA column, acetonitrile/water (45:55), 1.0 mL min⁻¹, 25 °C). The powder was redissolved in 15 mL of boiling absolute ethanol and left untouched for 50 minutes at room temperature. After 30 minutes fibers had formed, which were filtered off after an additional 20 minutes. This resulted in (*R*)-3'-diallylaminoblebbistatin (*R*)-12 (0.160 g, 16%) as bright orange cotton-like fibers with an enantiomeric excess of 98%.


(*R*)-1-(3-(diallyl-amino)phenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4*H*-pyrrolo[2,3-*b*]quinolin-4 one ((*R*)-12)



Yield = 16%. Bright orange cotton-like fibers (from absolute ethanol, mp 167 °C). **ee** 98%, chiral HPLC: t_R ((*R*)-11) = 31.1 min, t_R ((*S*)-11) = 27.7 min (Daicel Chiralpak IA column, acetonitrile/water (45:55), 1.0 mL min⁻¹, 25 °C). $[\alpha]_D^{25} = +327 \pm 3$ ($c = 0.18$ in tetrahydrofuran).

¹H NMR (400 MHz, DMSO-*d*₆): δ = 2.19–2.27 (m, 2H), 2.30 (s, 3H), 3.87–3.95 (m, 1H), 3.94–4.07 (m, 5H), 3.12–5.24 (m, 4H), 5.92 (ddt, $J = 17.1, 10.2, 5.1$ Hz, 2H), 6.47 (dd, $J = 8.1, 2.0$ Hz, 1H), 6.79 (s, 1H), 6.98 (dd, $J = 8.1, 2.0$ Hz, 1H), 7.07 (d, $J = 8.1$ Hz, 1H), 7.15 (t, $J = 8.1$ Hz, 1H), 7.38 (dd, $J = 8.1, 1.8$ Hz, 1H), 7.52 (d, $J = 1.8$ Hz, 1H), 7.94 (t, $J = 2.0$ Hz, 1H). **¹³C NMR** (100.6 MHz, DMSO-*d*₆): δ = 20.7, 28.8, 47.9, 53.0, 73.5, 104.8, 107.4, 108.3, 116.4, 121.4, 126.2, 126.8, 129.4, 132.5, 134.8, 137.0, 141.9, 148.9, 149.8, 165.7, 195.1. **MS** (ESI): m/z (%) = 387.5 ($[M+H]^+$, 100). **HRMS** (ESI): calculated for C₂₄H₂₆N₃O₂ ($[M+H]^+$) 388.2020; found 388.2023. **MW** = 387.47. Chiral HPLC chromatogram is provided in Figure S59.

1.12. Synthesis of diazomethane (CH₂N₂)



CAUTION! Diazomethane is a toxic and explosive compound! When dealing with diazomethane, the experimenter should first thoroughly study the literature on the properties and safe generation and handling of this hazardous reagent!^{16,17} **The synthesis must be carried out in a properly working hood using dedicated and thoroughly inspected equipment! Do not use sharp-edged glassware or ground joints!**

A 250 mL distilling flask was fitted with a condenser set for distillation and with a dropping funnel by means of special cork stoppers. The condenser was connected to an L-shaped glass tube which in his turn was connected to an ice-cooled 250 mL Büchner flask by means of special cork stoppers. Pressure build-up has to be avoided by means of an opening to the environment.

A solution of 2.14 g of *N*-methyl-*N*-nitroso-*para*-toluenesulfonamide (**S12**) (10.0 mmol, 1 equiv) in 25 mL of diethyl ether was added to the distilling flask which was cooled to 0 °C. A solution of 0.561 g of KOH (10.0 mmol, 1 equiv) in 60 mL of absolute ethanol was added dropwise by means of an addition funnel (without mechanical stirring!). After complete addition, a solution of diazomethane in diethyl ether was distilled off by heating the reaction mixture to 60 °C for about 30 minutes, using a warm (**but CERTAINLY BELOW 70 °C**) water bath. **CAUTION! At no time the water should boil! Never use other means of heating! Diazomethane may explode at 100 °C!** During distillation, diethyl ether was added *via* the dropping funnel until the distillate turned colorless. The yellow distillate, a dilute solution of diazomethane in diethyl ether, was collected in a Büchner flask cooled to 0 °C. **CAUTION! Explosion hazard! The solution should be dilute!**

2. X-ray crystallographic data

For the reported structures, X-ray intensity data were collected, at 100 K, on an Agilent Supernova Dual Source (Cu at zero) diffractometer equipped with an Atlas CCD detector using ω scans and CuK α ($\lambda = 1.54184$ Å) radiation. The images were interpreted and integrated with the program CrysAlisPro (Rigaku Oxford Diffraction).¹⁸ Using Olex2,¹⁹ the structures were solved by direct methods using the ShelXS structure solution program and refined by full-matrix least-squares on F^2 using the ShelXL program package.²⁰ Non-hydrogen atoms were anisotropically refined and the hydrogen atoms in the riding mode and isotropic temperature factors fixed at 1.2 times $U(\text{eq})$ of the parent atoms (1.5 times $U(\text{eq})$ for methyl and hydroxyl groups).

CCDC 1485738 and 1485739 contain the supplementary crystallographic data for this paper and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-1223-336033; or deposit@ccdc.cam.ac.uk).

2.1. X-ray crystallographic data of (S)-2

Crystal data for compound (S)-2. $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}_3$, $M = 308.33$, orthorhombic, space group $P2_12_12_1$ (No. 19), $a = 4.87924(5)$ Å, $b = 14.43858(15)$ Å, $c = 20.3657(2)$ Å, $V = 1434.75(3)$ Å³, $Z = 4$, $T = 100$ K, $\rho_{\text{calc}} = 1.427$ g cm⁻³, $\mu(\text{Cu-K}\alpha) = 0.805$ mm⁻¹, $F(000) = 648$, 63297 reflections measured, 2948 unique ($R_{\text{int}} = 0.1028$) which were used in all calculations. The final $R1$ was 0.0477 ($I > 2\sigma(I)$) and $wR2$ was 0.1282 (all data).




Figure S1. Molecular structure of compound (S)-2, showing thermal displacement ellipsoids at the 50% probability level and atom labeling scheme of the non-hydrogen atoms.




Figure S2. Packing in the crystal structure of compound (*S*)-2, along the *a*-axis. Hydrogen bonds, formed between the hydroxyl groups, are indicated.

2.2. X-ray crystallographic data of (R)-2

Crystal data for compound (R)-2. $C_{18}H_{16}N_2O_3$, $M = 308.33$, orthorhombic, space group $P2_12_12_1$ (No. 19), $a = 4.88084(6)$ Å, $b = 14.45507(15)$ Å, $c = 20.3743(2)$ Å, $V = 1437.47(3)$ Å³, $Z = 4$, $T = 100$ K, $\rho_{\text{calc}} = 1.425$ g cm⁻³, $\mu(\text{Cu-K}\alpha) = 0.803$ mm⁻¹, $F(000) = 648$, 31031 reflections measured, 49208 unique ($R_{\text{int}} = 0.1088$) which were used in all calculations. The final $R1$ was 0.0498 ($I > 2\sigma(I)$) and $wR2$ was 0.0498 (all data).




Figure S3. Molecular structure of compound (R)-2, showing thermal displacement ellipsoids at the 50% probability level and atom labeling scheme of the non-hydrogen atoms.




Figure S4. Packing in the crystal structure of compound (*R*)-2, along the *a*-axis. Hydrogen bonds, formed between the hydroxyl groups, are indicated.

3. ¹H NMR spectra, ¹³C NMR spectra and LC-MS chromatograms




Figure S5. ^1H NMR spectrum of **4b**.




Figure S6. ^1H NMR spectrum of **4c**.




Figure S7. ^{13}C NMR spectrum of **4c**.




Figure S8. ^1H NMR spectrum of **S6**.




Figure S9. ^1H NMR spectrum of **6a**.




Figure S10. ^1H NMR spectrum of **6b**.




Figure S11. ^{13}C NMR spectrum of **6b**.




Figure S12. ^1H NMR spectrum of **6d**.






Figure S15. ^{13}C NMR spectrum of **6c**.




Figure S16. ^1H NMR spectrum of **10**.




Figure S17. ¹³C NMR spectrum of **10**.




Figure S18. ¹H NMR spectrum of **7**.




Figure S21. ^{13}C NMR spectrum of **8b**.




Figure S22. ^1H NMR spectrum of **8d**.




Figure S23. ^{13}C NMR spectrum of **8d**.




Figure S24. ^1H NMR spectrum of **9a**.






Figure S27. ¹H NMR spectrum of 9d.




Figure S28. ¹³C NMR spectrum of 9d.






Figure S31. ^{13}C NMR spectrum of (*S*)-11.




Figure S32. ^1H NMR spectrum of (*S*)-13.






Figure S35. ¹³C NMR spectrum of (S)-12.




Figure S36. ¹H NMR spectrum of (S)-2.




Figure S37. ¹³C NMR spectrum of (S)-2.




Figure S38. ¹H NMR spectrum of (S)-3.




Figure S39. ¹³C NMR spectrum of (S)-3.




Figure S40. ¹H NMR spectrum of (S)-16.




Figure S41. ^{13}C NMR spectrum of (*S*)-16.




Figure S42. ^1H NMR spectrum of (*S*)-17.




Figure S43. ^{13}C NMR spectrum of (S)-17.




Figure S44. Proof of formation of corresponding methyl ester of (S)-17 via ^1H NMR (overlay of (S)-17).




Figure S45. Proof of formation of corresponding methyl ester of (*S*)-17 via LC.




Figure S46. Proof of formation of corresponding methyl ester of (*S*)-17 via MS (MS-spectrum of compound with $t_R = 0.324$ min in Figure S45).




Figure S47. Proof of formation of corresponding methyl ester of (*S*)-**17** *via* MS (MS-spectrum of compound with $t_R = 2.606$ min in Figure S45).

4. Chiral HPLC chromatograms






Figure S48. Chiral HPLC chromatogram of (*S*)-**1** spiked with (*R*)-**1**.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.323	BB	0.3873	2.87565e4	1151.78931	100.0000
Totals :				2.87565e4	1151.78931	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.323	BB	0.3836	1.28542e4	521.51294	100.0000
Totals :				1.28542e4	521.51294	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.323	BB	0.3825	9053.86914	368.64407	100.0000
Totals :				9053.86914	368.64407	
*** End of Report ***						

Figure S49. Chiral HPLC chromatogram of (S)-1.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.306	MM	0.4439	90.45800	3.39619	0.4286
2	9.772	BB	0.7747	2.10152e4	416.46057	99.5714
Totals :				2.11057e4	419.85677	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.308	MM	0.4416	41.44268	1.56393	0.4441
2	9.772	BB	0.7687	9289.46973	185.36247	99.5559
Totals :				9330.91241	186.92641	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.302	MM	0.3934	24.31529	1.03012	0.3682
2	9.772	BB	0.7720	6578.78711	131.42290	99.6318
Totals :				6603.10240	132.45302	
*** End of Report ***						

Figure S50. Chiral HPLC chromatogram of (*R*)-1.






Figure S51. Chiral HPLC chromatogram of (*S*)-**11** spiked with (*R*)-**11**.



Area Percent Report						
Signal 1: DAD1 A, Sig=268Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.169	BB	0.6729	3.38424e4	769.84790	100.0000
Totals :				3.38424e4	769.84790	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.169	BB	0.6684	2.18080e4	498.43903	100.0000
Totals :				2.18080e4	498.43903	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.170	BB	0.6643	1.04204e4	239.15958	100.0000
Totals :				1.04204e4	239.15958	
*** End of Report ***						

Figure S52. Chiral HPLC chromatogram of (*S*)-11.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.200	BB	0.8613	1.93767e4	348.15967	100.0000
Totals :				1.93767e4	348.15967	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.201	BB	0.8504	1.24005e4	223.81982	100.0000
Totals :				1.24005e4	223.81982	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	14.201	BB	0.8413	5921.57861	107.39657	100.0000
Totals :				5921.57861	107.39657	
*** End of Report ***						

Figure S53. Chiral HPLC chromatogram of (*R*)-11.






Figure S54. Chiral HPLC chromatogram of (*S*)-**13** spiked with (*R*)-**13**.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.682	BB	0.3997	2.88199e4	1107.00513	91.2478
2	10.058	BB	0.6109	2764.30127	69.66653	8.7522
Totals :				3.15842e4	1176.67166	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.682	BB	0.3990	3.21849e4	1239.12463	91.2803
2	10.058	BB	0.6093	3074.50684	77.41396	8.7197
Totals :				3.52594e4	1316.53860	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.682	BB	0.3976	1.18118e4	456.91171	91.3423
2	10.058	BB	0.6065	1119.56445	28.36450	8.6577
Totals :				1.29314e4	485.27621	
*** End of Report ***						

Figure S55. Chiral HPLC chromatogram of (S)-13.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.672	BB	0.3327	2570.77197	118.67730	7.8563
2	9.877	BB	0.6827	3.01517e4	667.91925	92.1437
Totals :				3.27224e4	786.59655	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.672	BB	0.3476	3097.24463	135.04044	7.8597
2	9.878	BB	0.7090	3.63092e4	760.50641	92.1403
Totals :				3.94064e4	895.54684	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	7.672	BB	0.3323	1040.56470	48.50504	7.8915
2	9.877	BB	0.6694	1.21454e4	273.87204	92.1085
Totals :				1.31859e4	322.37708	
*** End of Report ***						

Figure S56. Chiral HPLC chromatogram of (*R*)-13.






Figure S57. Chiral HPLC chromatogram of (*S*)-12 spiked with (*R*)-12.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	27.128	BB	1.3829	6.08378e4	667.77954	100.0000
Totals :				6.08378e4	667.77954	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	27.128	BB	1.3808	3.59935e4	397.36972	100.0000
Totals :				3.59935e4	397.36972	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	27.127	BB	1.3393	1.47638e4	164.14957	100.0000
Totals :				1.47638e4	164.14957	
*** End of Report ***						

Figure S58. Chiral HPLC chromatogram of (*S*)-12.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	27.673	MF	1.3623	871.79840	10.66553	0.8416
2	31.127	FM	2.0364	1.02721e5	840.72552	99.1584
Totals :				1.03593e5	851.39105	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	27.694	MF	1.4911	607.42621	6.78967	0.9820
2	31.129	FM	2.0307	6.12460e4	502.67957	99.0180
Totals :				6.18535e4	509.46924	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	27.678	MF	1.3385	206.94585	2.57690	0.8111
2	31.130	FM	2.0282	2.53068e4	207.96075	99.1889
Totals :				2.55137e4	210.53765	
*** End of Report ***						

Figure S59. Chiral HPLC chromatogram of (*R*)-12.






Figure S60. Chiral HPLC chromatogram of (*S*)-**2** spiked with (*R*)-**2**.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.873	VV	0.2874	4.12882e4	2136.97314	99.5102
2	5.177	MM	0.3361	203.22523	10.07786	0.4898
Totals :				4.14914e4	2147.05101	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.874	VB	0.2519	2.73658e4	1581.08496	99.3489
2	5.160	MM	0.4011	179.34746	7.45250	0.6511
Totals :				2.75451e4	1588.53747	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.873	BB	0.2471	1.33921e4	792.67151	100.0000
Totals :				1.33921e4	792.67151	
*** End of Report ***						

Figure S61. Chiral HPLC chromatogram of (*S*)-**2**.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.909	MM	0.2895	223.11160	12.84487	0.9448
2	5.114	BB	0.4409	2.33913e4	800.55347	99.0552
Totals :				2.36144e4	813.39834	
Signal 2: DAD1 B, Sig=234 Ref=332						
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	3.902	MM	0.2626	62.92564	3.99308	0.9004
2	5.114	BB	0.4367	6925.93701	239.98106	99.0996
Totals :				6988.86266	243.97414	
*** End of Report ***						

Figure S62. Chiral HPLC chromatogram of (*R*)-2.






Figure S63. Chiral HPLC chromatogram of (*S*)-**3** spiked with (*R*)-**3**.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.405	BB	0.2861	4.11661e4	2181.87695	100.0000
Totals :				4.11661e4	2181.87695	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.409	VB	0.2707	3.80011e4	2104.52466	100.0000
Totals :				3.80011e4	2104.52466	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.407	VB	0.2481	1.46083e4	877.95654	100.0000
Totals :				1.46083e4	877.95654	
*** End of Report ***						

Figure S64. Chiral HPLC chromatogram of (*S*)-3.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.435	BB	0.2544	664.35297	39.07228	2.3951
2	6.347	VB	0.5575	2.70738e4	745.89117	97.6049
Totals :				2.77381e4	784.96345	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.432	MM	0.2649	533.29248	33.55628	2.2503
2	6.347	VB	0.5576	2.31657e4	638.06116	97.7497
Totals :				2.36990e4	671.61744	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	4.438	BB	0.2553	215.70221	12.49881	2.3778
2	6.347	BB	0.5509	8855.63086	245.45146	97.6222
Totals :				9071.33307	257.95027	
*** End of Report ***						

Figure S65. Chiral HPLC chromatogram of (*R*)-**3**.






Figure S66. Chiral HPLC chromatogram of (*S*)-**16** spiked with (*R*)-**16**.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.601	BB	0.5252	317.24835	8.70569	1.0604
2	20.940	BB	0.6337	2.95999e4	696.71820	98.9396
Totals :				2.99171e4	705.42389	
Signal 2: DAD1 B, Sig=234 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.604	BB	0.4516	307.24445	8.42317	1.1065
2	20.940	BB	0.6315	2.74591e4	646.46808	98.8935
Totals :				2.77663e4	654.89125	
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.600	BB	0.4188	74.67025	2.33699	0.7036
2	20.940	BB	0.6148	1.05373e4	254.60912	99.2964
Totals :				1.06119e4	256.94611	
*** End of Report ***						

Figure S67. Chiral HPLC chromatogram of (S)-16.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.344	MF	0.6593	1716.79102	43.40181	98.1276
2	21.435	FM	0.8589	32.75820	6.35648e-1	1.8724
Totals :				1749.54921	44.03746	
Signal 2: DAD1 B, Sig=234 Ref=332						
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	17.343	MF	0.6173	527.94348	14.25369	98.7468
2	21.495	FM	0.7191	6.70038	1.55299e-1	1.2532
Totals :				534.64386	14.40899	
*** End of Report ***						

Figure S68. Chiral HPLC chromatogram of (*R*)-16.






Figure S69. Chiral HPLC chromatogram of corresponding methyl ester of (*S*)-**17** spiked with corresponding methyl ester of (*R*)-**17**.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	61.585	MF	3.3990	4836.27002	23.71438	97.9039
2	73.611	FM	3.9964	103.54269	4.31814e-1	2.0961
Totals :				4939.81271	24.14620	
Signal 2: DAD1 B, Sig=234 Ref=332						
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	61.628	MF	3.4460	1646.15820	7.96159	98.7528
2	73.801	FM	3.0216	20.79068	1.14679e-1	1.2472
Totals :				1666.94889	8.07627	
*** End of Report ***						

Figure S70. Chiral HPLC chromatogram of corresponding methyl ester of (*S*)-17.



Area Percent Report						
Signal 1: DAD1 A, Sig=268 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	62.709	MF	3.3176	134.67136	6.76541e-1	4.1551
2	73.266	FM	4.6232	3106.40894	11.19864	95.8449
Totals :				3241.08029	11.87518	
Signal 2: DAD1 B, Sig=234 Ref=332						
Signal 3: DAD1 C, Sig=296 Ref=332						
Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	62.889	MM	3.6880	55.83808	2.52340e-1	5.1917
2	73.240	MM	4.6262	1019.69373	3.67362	94.8083
Totals :				1075.53181	3.92596	
*** End of Report ***						

Figure S71. Chiral HPLC chromatogram of corresponding methyl ester of (*R*)-17.

5. Actin-activated ATPase assay



Figure S72. Observed (*S*)-13 precipitation in assay buffer when applied at concentrations higher than 40 μ M.

6. Microscopic imaging of fluorescence




Figure S73. Fluorescence imaging of GFP-negative MCF-7/6 breast carcinoma cells treated with 0.1% DMSO as a solvent control. (A) Brightfield image. (B) Fluorescence image (488 nm excitation).




Figure S74. Fluorescence imaging of GFP-negative MCF-7/6 breast carcinoma cells treated with 5 μM of (S)-3'-aminoblebbistatin (S)-3. (A) Brightfield image. (B) Fluorescence image (488 nm excitation).




Figure S75. Fluorescence imaging of GFP-negative MCF-7/6 human breast carcinoma cells treated with (*S*)-3'-hydroxyblebbistatin (*S*)-**2**. (A) Brightfield image and (B) fluorescence image (488 nm excitation) of treatment with 5 μ M of (*S*)-3'-hydroxyblebbistatin (*S*)-**2**. (C) Brightfield image and (D) fluorescence image (488 nm excitation) of treatment with 50 μ M of (*S*)-3'-hydroxyblebbistatin (*S*)-**2**.

7. References

1. D. H. Brown Ripin and M. Vetelino, *Synlett*, 2003, **15**, 2353-2353.
2. S. Buchan and H. McCombie, *J. Chem. Soc.*, 1932, 2857-2860.
3. A. Dahlen, A. Petersson and G. Hilmersson, *Org. Biomol. Chem.*, 2003, **1**, 2423-2426.
4. S. Vandekerckhove, S. Van Herreweghe, J. Willems, B. Danneels, T. Desmet, C. de Kock, P. J. Smith, K. Chibale and M. D'Hooghe, *Eur. J. Med. Chem.*, 2015, **92**, 91-102.
5. D. L. Reger, T. C. Grattan, K. J. Brown, C. A. Little, J. J. S. Lamba, A. L. Rheingold and R. D. Sommer, *J. Organomet. Chem.*, 2000, **607**, 120-128.
6. S. Trofimenko, *J. Am. Chem. Soc.*, 1970, **92**, 5118-5126.
7. S. Juliá, J. M. del Mazo, L. Avila and J. Elguero, *Org. Prep. Proc. Int.*, 1984, **16**, 299-307.
8. E. Haldón, E. Álvarez, M. C. Nicasio and P. J. Pérez, *Inorg. Chem.*, 2012, **51**, 8298-8306.
9. P. Lipp and F. Caspers, *Ber. Dtsch. Chem. Ges. B: Abhandlungen*, 1925, **58B**, 1011-1014.
10. H.-J. Cristau, P. P. Cellier, J.-F. Spindler and M. Taillefer, *Chem. Eur. J.*, 2004, **10**, 5607-5622.
11. J. Ackermann, K. Bleicher, S. Ceccarelli Grenz, O. Chomienne, P. Mattei, T. Schulz-Gasch. WO 2007/063012 A1, 2007.
12. C. P. A. T. Lawson, A. M. Z. Slawin and N. J. Westwood, *Chem. Commun.*, 2011, **47**, 1057-1059.
13. I. Niculescu-Duvaz, M. Ionescu, A. Cambanis, M. Vitan and V. Feyns, *J. Med. Chem.*, 1968, **11**, 500-503.
14. E. Schuler, N. Juanico, J. Teixido, E. L. Michelotti and J. I. Borrell, *Heterocycles*, 2006, **67**, 161-173.
15. C. Lucas-Lopez, S. Patterson, T. Blum, A. F. Straight, J. Toth, A. M. Z. Slawin, T. J. Mitchison, J. R. Sellers and N. J. Westwood, *Eur. J. Org. Chem.*, 2005, 1736-1740.
16. Center For Disease Control and Prevention. Diazomethane. <http://www.cdc.gov/niosh/ipcsneng/neng1256.html>, (accessed February 2016).
17. International Programme on Chemical Safety. Diazomethane. <http://www.inchem.org/documents/icsc/icsc/eics1256.htm>, (accessed February 2016).
18. Rigaku Oxford Diffraction (2015). *CrysAlis PRO*. Rigaku Oxford Diffraction, Yarnton, England.
19. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Cryst.*, 2009, **42**, 339-341.
20. G. M. Sheldrick, *Acta Crystallogr.*, 2008, **A64**, 112-122.